JP2005514380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514380A5 JP2005514380A5 JP2003548831A JP2003548831A JP2005514380A5 JP 2005514380 A5 JP2005514380 A5 JP 2005514380A5 JP 2003548831 A JP2003548831 A JP 2003548831A JP 2003548831 A JP2003548831 A JP 2003548831A JP 2005514380 A5 JP2005514380 A5 JP 2005514380A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydroxy
- benzyl
- phenylpentyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims 220
- 229910052799 carbon Inorganic materials 0.000 claims 90
- 229910052739 hydrogen Inorganic materials 0.000 claims 90
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 88
- 125000000623 heterocyclic group Chemical group 0.000 claims 50
- 229910052760 oxygen Inorganic materials 0.000 claims 50
- 229910052717 sulfur Inorganic materials 0.000 claims 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims 30
- -1 benzopiperidinyl Chemical group 0.000 claims 28
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 20
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 10
- 210000004899 c-terminal region Anatomy 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000001041 indolyl group Chemical group 0.000 claims 10
- 229910021645 metal ion Inorganic materials 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims 5
- LIVPIXYPZUWCBQ-HUASTKEASA-N tert-butyl n-[(2s,3s)-3-hydroxy-1,6-diphenyl-5-(5-propyl-1,3-thiazol-2-yl)hexan-2-yl]carbamate Chemical compound S1C(CCC)=CN=C1C(CC=1C=CC=CC=1)C[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 LIVPIXYPZUWCBQ-HUASTKEASA-N 0.000 claims 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 210000004227 basal ganglia Anatomy 0.000 claims 2
- HAYMYKDNVZCIIM-OCSVHVNCSA-N benzyl n-[(2s)-1-[[(2s,3s)-3-hydroxy-1,6-diphenyl-5-(5-propyl-1,3-thiazol-2-yl)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound S1C(CCC)=CN=C1C(CC=1C=CC=CC=1)C[C@H](O)[C@@H](NC(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)C(C)C)CC1=CC=CC=C1 HAYMYKDNVZCIIM-OCSVHVNCSA-N 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- NPBXTHKOPGZFJL-QIFDKBNDSA-N 2-[(4s,5s)-4-hydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]-1,3-thiazole-5-carboxylic acid Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(=CN=1)C(O)=O)C1=CC=CC=C1 NPBXTHKOPGZFJL-QIFDKBNDSA-N 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- NHAXFCUJGHFYSE-WXNGITDCSA-N benzyl n-[(2s)-1-[[(2s,3s)-3-hydroxy-1,6-diphenyl-5-(5-propyl-1,3-thiazol-2-yl)hexan-2-yl]amino]-1-oxopropan-2-yl]carbamate Chemical compound S1C(CCC)=CN=C1C(CC=1C=CC=CC=1)C[C@H](O)[C@@H](NC(=O)[C@H](C)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 NHAXFCUJGHFYSE-WXNGITDCSA-N 0.000 claims 1
- XKXSQWPGOJDKPI-KEKPXRHTSA-N benzyl n-[amino-[[2-[(4s,5s)-4-hydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]-1,3-thiazole-5-carbonyl]amino]methylidene]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(=CN=1)C(=O)NC(N)=NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 XKXSQWPGOJDKPI-KEKPXRHTSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 claims 1
- 230000000508 neurotrophic effect Effects 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- UDORCWIHOOQQFA-DCUVQVOZSA-N tert-butyl (2s,3s,5r)-2-[amino(phenyl)methyl]-3-hydroxy-5-(5-hydroxy-6,6-dimethyl-7-oxo-5h-pyrrolo[1,2-c]imidazol-3-yl)-6-phenylhexanoate Chemical compound C([C@H](C[C@H](O)[C@@H](C(=O)OC(C)(C)C)C(N)C=1C=CC=CC=1)C=1N2C(O)C(C)(C)C(=O)C2=CN=1)C1=CC=CC=C1 UDORCWIHOOQQFA-DCUVQVOZSA-N 0.000 claims 1
- ABUOQJYUTHZSHT-HUASTKEASA-N tert-butyl N-[(2S,3S)-3-hydroxy-5-[5-(3-hydroxypropyl)-1,3-thiazol-2-yl]-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(CCCO)=CN=1)C1=CC=CC=C1 ABUOQJYUTHZSHT-HUASTKEASA-N 0.000 claims 1
- PVPPHFPSWBSHQG-KXNJDZORSA-N tert-butyl n-[(2s,3s)-3-hydroxy-1,6-diphenyl-5-(1,3-thiazol-2-yl)hexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC=CN=1)C1=CC=CC=C1 PVPPHFPSWBSHQG-KXNJDZORSA-N 0.000 claims 1
- XHMJMUASXPJSAD-QIFDKBNDSA-N tert-butyl n-[(2s,3s)-3-hydroxy-1,6-diphenyl-5-(1h-1,2,4-triazol-5-yl)hexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1NN=CN=1)C1=CC=CC=C1 XHMJMUASXPJSAD-QIFDKBNDSA-N 0.000 claims 1
- NGMCNEDPAAWIHS-HPZMQGABSA-N tert-butyl n-[(2s,3s)-3-hydroxy-1,6-diphenyl-5-(5-propanoyl-1,3-thiazol-2-yl)hexan-2-yl]carbamate Chemical compound S1C(C(=O)CC)=CN=C1C(CC=1C=CC=CC=1)C[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 NGMCNEDPAAWIHS-HPZMQGABSA-N 0.000 claims 1
- OVUHBKOXJLOSRY-XRKSGAARSA-N tert-butyl n-[(2s,3s)-3-hydroxy-5-[5-(1-hydroxy-2-methylpropyl)-1,3-thiazol-2-yl]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(O)C(C)C)=CN=C1C(CC=1C=CC=CC=1)C[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 OVUHBKOXJLOSRY-XRKSGAARSA-N 0.000 claims 1
- JWLUWRQTSIPJQS-CZKABKHRSA-N tert-butyl n-[(2s,3s)-3-hydroxy-5-[5-(1-hydroxypropyl)-1,3-thiazol-2-yl]-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(C(O)CC)=CN=C1C(CC=1C=CC=CC=1)C[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 JWLUWRQTSIPJQS-CZKABKHRSA-N 0.000 claims 1
- KCIAAYVOCSGDJX-BCXZNTRWSA-N tert-butyl n-[(2s,3s)-3-hydroxy-5-[5-(hydroxymethyl)-1,3-thiazol-2-yl]-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(CO)=CN=1)C1=CC=CC=C1 KCIAAYVOCSGDJX-BCXZNTRWSA-N 0.000 claims 1
- RUIXGEYDNKLREW-MLYQVHPVSA-N tert-butyl n-[(2s,3s)-3-hydroxy-5-[5-[hydroxy(phenyl)methyl]-1,3-thiazol-2-yl]-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(=CN=1)C(O)C=1C=CC=CC=1)C1=CC=CC=C1 RUIXGEYDNKLREW-MLYQVHPVSA-N 0.000 claims 1
- AOZMSTSSWQEQHX-UWDVWBIHSA-N tert-butyl n-[(2s,3s)-5-(5-benzoyl-1,3-thiazol-2-yl)-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(=CN=1)C(=O)C=1C=CC=CC=1)C1=CC=CC=C1 AOZMSTSSWQEQHX-UWDVWBIHSA-N 0.000 claims 1
- GANVKYDRBGUCSB-QIFDKBNDSA-N tert-butyl n-[(2s,3s)-5-(5-carbamoyl-1,3-thiazol-2-yl)-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(=CN=1)C(N)=O)C1=CC=CC=C1 GANVKYDRBGUCSB-QIFDKBNDSA-N 0.000 claims 1
- BMTYUQASEHNVDJ-GARJWBAXSA-N tert-butyl n-[(2s,3s)-5-(5-ethyl-1,3-thiazol-2-yl)-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(CC)=CN=C1C(CC=1C=CC=CC=1)C[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 BMTYUQASEHNVDJ-GARJWBAXSA-N 0.000 claims 1
- PWFRMGLBHCVFNE-BCXZNTRWSA-N tert-butyl n-[(2s,3s)-5-(5-formyl-1,3-thiazol-2-yl)-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(C=O)=CN=1)C1=CC=CC=C1 PWFRMGLBHCVFNE-BCXZNTRWSA-N 0.000 claims 1
- LUBRXGLXGIUFII-XZZNXKJUSA-N tert-butyl n-[(2s,3s)-5-[5-(1,2-dihydroxyethyl)-1,3-thiazol-2-yl]-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)CC(CC=1C=CC=CC=1)C=1SC(=CN=1)C(O)CO)C1=CC=CC=C1 LUBRXGLXGIUFII-XZZNXKJUSA-N 0.000 claims 1
- FTGKBDGHVLTNIC-STXQHDJLSA-N tert-butyl n-[(2s,3s,5r)-5-(5-butyl-1,3-thiazol-2-yl)-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound S1C(CCCC)=CN=C1[C@H](CC=1C=CC=CC=1)C[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 FTGKBDGHVLTNIC-STXQHDJLSA-N 0.000 claims 1
- 125000002114 valyl group Chemical group 0.000 claims 1
- 0 *C(C(C(C(C1=NC*=C(*)C1)[U+])[U])O)N(*)* Chemical compound *C(C(C(C(C1=NC*=C(*)C1)[U+])[U])O)N(*)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33656601P | 2001-12-04 | 2001-12-04 | |
| PCT/US2002/040038 WO2003047576A1 (en) | 2001-12-04 | 2002-12-03 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514380A JP2005514380A (ja) | 2005-05-19 |
| JP2005514380A5 true JP2005514380A5 (enExample) | 2006-02-02 |
Family
ID=23316667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003548831A Abandoned JP2005514380A (ja) | 2001-12-04 | 2002-12-03 | アルツハイマー病の治療に有用な複素環を含むペプチドアイソスター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050159460A1 (enExample) |
| EP (1) | EP1450795A1 (enExample) |
| JP (1) | JP2005514380A (enExample) |
| AU (1) | AU2002357232A1 (enExample) |
| BR (1) | BR0214731A (enExample) |
| CA (1) | CA2469130A1 (enExample) |
| MX (1) | MXPA04005451A (enExample) |
| WO (1) | WO2003047576A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004002478A1 (en) * | 2002-06-27 | 2004-01-08 | Elan Pharmaceuticals, Inc. | Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| MXPA06012391A (es) * | 2004-04-30 | 2007-01-31 | Theraptosis S A | Inhibidores de caspasa-2 y sus aplicaciones biologicas. |
| WO2007002220A2 (en) * | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as beta-secretase inhibitors |
| WO2007002214A2 (en) * | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Acyl guanidines as beta-secretase inhibitors |
| WO2009005783A1 (en) * | 2007-06-28 | 2009-01-08 | Blanchette Rockefeller Neurosciences Institute | Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis |
| WO2009080773A1 (en) * | 2007-12-24 | 2009-07-02 | Dsm Ip Assets B.V. | Convergent synthesis of renin inhibitors and intermediates useful therein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| TR199901128T2 (xx) * | 1996-11-22 | 1999-07-21 | Elan Pharmaceuticals, Inc. | N-(aril/heteroarilasetil) amino asit esterler, bunu ihtiva eden farmas�tik bile�imler ve bu t�r bile�ikler kullanarak �-amiloit peptit sal�n�m�n� ve/veya bunun sentezlenmesini inhibe etme y�ntemleri. |
| JP2003528071A (ja) * | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| ATE302751T1 (de) * | 2000-06-30 | 2005-09-15 | Elan Pharm Inc | Verbindungen zur behandlung der alzheimerischen krankheit |
-
2002
- 2002-12-03 CA CA002469130A patent/CA2469130A1/en not_active Abandoned
- 2002-12-03 BR BR0214731-9A patent/BR0214731A/pt not_active IP Right Cessation
- 2002-12-03 EP EP02804521A patent/EP1450795A1/en not_active Withdrawn
- 2002-12-03 AU AU2002357232A patent/AU2002357232A1/en not_active Abandoned
- 2002-12-03 JP JP2003548831A patent/JP2005514380A/ja not_active Abandoned
- 2002-12-03 MX MXPA04005451A patent/MXPA04005451A/es not_active Application Discontinuation
- 2002-12-03 WO PCT/US2002/040038 patent/WO2003047576A1/en not_active Ceased
- 2002-12-03 US US10/497,810 patent/US20050159460A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| WO2004094384A3 (en) | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease | |
| JP2005524628A5 (enExample) | ||
| WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| EP3630101B1 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| WO2001012171A3 (en) | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases | |
| AP2004002952A0 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds. | |
| KR20010079616A (ko) | 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도 | |
| WO2003027068A3 (en) | Substituted amines for the treatment of neurological disorders | |
| US10016397B2 (en) | Selective AT2 receptor agonists for use in treatment of cachexia | |
| WO2007056219A3 (en) | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | |
| US20050107356A1 (en) | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | |
| JP2005508940A5 (enExample) | ||
| WO2002100818A3 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| MX2008016083A (es) | Metodo para modular la excrecion de neuritas por el uso de un antagonista del receptor de galanina-3. | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| JP2005514380A5 (enExample) | ||
| JP2014527542A (ja) | 骨がんの治療に使用するためまたは原発がん細胞の骨への転移性播種を予防するためのｐｉ３ｋ阻害剤 | |
| JP4841433B2 (ja) | 治療的処置 | |
| JP2005514370A5 (enExample) | ||
| CA2680324A1 (en) | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | |
| JP2008534541A5 (enExample) | ||
| JP2018502911A5 (enExample) | ||
| JP2010531854A5 (enExample) |